SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant
Origin species
SARS-COV2
Expression system
Eukaryotic expression
Sequence
YP_009724390.1
Molecular weight
27kDa
Buffer
PBS, pH7.5
Form
Liquid
Delivery condition
Dry Ice
Storage condition
4°C for short term; -20°c or -80°C for long term
Brand
ProteoGenix
Host species
Mammalian cells
Fragment Type
Spike protein fragment
Aliases /Synonyms
B.1.1.529, Omicron variant, lineage B.1.1.529, South Africa variant, Botswana variant
Reference
PX-COV-P074
Note
For research use only. Not suitable for human use.
Description of SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant
General information on SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant
Lineage B.1.1.529 was reported to WHO in late November 2021 in South Africa. This variant of SARS-CoV-2 accumulates an unprecedented high number of mutations on the spike protein, and especially receptor binding domain (RBD), compared to former variants involved in the Covid-19 pandemic.
The reported mutations are the following : A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211-212, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.
The consequences of these new mutations are not yet clear. Some of them had been detected in other variants. K417N and N501Y are typical mutations of the Beta variant from South Africa. S477N had been reported in a variant found in the USA, detected in December 2020, lineage B.1.526.2. Many other mutations are new to the scientific community and need to be studied. According to preliminary results, this new variant might be related to an increased reinfection rate. There are also evidences for a higher growth of the virus.
The PCR tests that have been deployed for other variants still detect it. The efficiency of market vaccines on the omicron variant is currently studied.
After spreading in all South African regions, the variant has been reported in other African countries such as Botswana and then in Europe.
More studies are necessary to determine the precise properties of this variant, especially the impacts of its unreported mutations on transmissibility and the severity its cases of Severe Acute Respiratory Syndrome.
SDS-PAGE for SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant
Publication
Hubert Bernauer, Anja Schlör, Josef Maier, Norbert Bannert, Katja Hanack, Daniel Ivanusic, tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain of SARS-CoV-2, Biology Methods and Protocols, Volume 8, Issue 1, 2023, bpad030, https://doi.org/10.1093/biomethods/bpad030
Winklmeier S, Rübsamen H, Özdemir C, Wratil PR, Lupoli G, Stern M, Schneider C, Eisenhut K, Ho S, Wong HK, Taskin D, Petry M, Weigand M, Eichhorn P, Foesel BU, Mader S, Keppler OT, Kümpfel T and Meinl E (2024) Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva. Front. Immunol. 15:1330864. doi: https://doi.org/10.3389/fimmu.2024.1330864
Reviews
Rated 5 out of 5
Emmanuel –
Worked for our uses. Originally used a free sample but will be ordering more!
Emmanuel –
Worked for our uses. Originally used a free sample but will be ordering more!